85-79-0 Categories: , ,
  • #LGM Pharma is a Dibucaine CAS# 85-79-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 85-79-0
  • AHFC code: 24:08.0
  • Synonyms: 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide, 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide, 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide, 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide, 4-22-00-02284 (Beilstein Handbook Reference), 4-Quinolinecarboxamide, 2-butoxy-N-(2-(diethylamino)ethyl)-, alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine, alpha-Butyloxycinchoninic acid diethylethylenediamide, BRN 0275489, Cincainum, Cinchocaine, Cinchocainum, Cinchocainum [INN-Latin], Cinchoninamide, 2-butoxy-N-(2-(diethylamino)ethyl)-, Cincocaina, Cincocaina [DCIT], Cincocainio, Cincocainio [INN-Spanish], Dermacaine, Dibucain, Dibucaine, Dibucaine Base, Dibucainum, EINECS 201-632-1, HSDB 3312, N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide, NSC 159055, Nupercainal, Nupercainal (VAN), Nupercaine, Percamine, Sovcaine, UNII-L6JW2TJG99
  • ATC Code: C05AD04" D04AB02" N01BB06" S01HA06" S02DA04
  • Chemical Formula: C20-H29-N3-O2
  • Molecular Weight: 343.4681
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00527 (APRD00915)
  • SMILES: c12c(cc(nc1cccc2)OCCCC)C(=O)NCCN(CC)CC
  • InChl: 1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
  • PubChem:
  • IUPAC: 4-Quinolinecarboxamide, 2-butoxy-N-(2-(diethylamino)ethyl)-

Additional Details

For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
Dibucaine is an amide-type local anesthetic, similar to lidocaine.
Mode of Action:
Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel inhibition. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
Primarily hepatic.
Subcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
General Reference:
Abdel-Ghani NT, Youssef AF, Awady MA: Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry. Farmaco. 2005 May;60(5):419-24. PubmedSouto-Padron T, Lima AP, Ribeiro Rde O: Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi. Parasitol Res. 2006 Sep;99(4):317-20. Epub 2006 Apr 13. PubmedNounou MM, El-Khordagui LK, Khalafallah N: Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm. 2005 Sep-Oct;62(5):369-79. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials


Related YouTube Videos